Inquire Before Buying - Malignant Melanoma Market Grow at CAGR of 7% by 2027

Global Malignant Melanoma Market Research Report: Forecast (2022-2027)

By Diagnosis (Biopsy, Blood Tests, Lab Tests, Imaging), By Treatment (Lymphadenectomy, Metastasectomy, Radiation Therapy, Chemotherapy, Immunotherapy (Yervoy (Ipilimumab), Keytruda...... (Pembrolizumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Relatlimab), Targeted Therapy (Mekinist (Trametinib), Tafinlar (Dabrafenib), Mektovi (Binimetinib), Braftovi (Encorafenib), Zelboraf (Vemurafenib), Others (Cotellic (Cobimetinib), etc.))) By End-User (Hospitals, Clinics, Specialty Cancer Centers), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific), By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia), By Company (AstraZeneca PLC, Amgen Inc., Bristol Myers Squibb, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Others) Read more

Healthcare
Jun 2022
Pages 185
Report Format: PDF, Excel, PPT

Market Definition

Malignant melanoma is a tumor produced by the neoplasm (uncontrolled growth) of melanocytes derived from the neural crest. It usually occurs on the skin but can further spread in other areas where neural crest cells migrate. Most melanomas in the early stages do not present any particular symptoms. However, later they may appear as an already existing mole that displays size/color differences or lesions that do not heal. Its prevalence is rapidly growing worldwide, more commonly among Whites than Blacks & Asians. Being aggressive in nature, it can spread to numerous atypical locations through metastasis and hence has a poor prognosis.

Market Insights

The Global Malignant Melanoma Market is projected to grow at around 7% CAGR during the forecast period, i.e., 2022-27. The mounting patient pool for skin cancer & other skin allergies, rapidly increasing penetration of novel therapeutic agents, high unmet patient needs for melanoma treatment, and the launch of premium-priced therapies, like the combination of PD-1 and BRAF/MEK inhibitors, are the prime aspects driving the global market.

Report Coverage	Details
Study Period	Historical Data: 2017-20
	Base Year: 2021
	Forecast Period: 2022-27
CAGR (2022-2027)	7%
Regions Covered	North America: The US, Canada, Mexico
	Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
	South America: Brazil, Rest of Latin America
	Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled	AstraZeneca PLC, Amgen Inc., Bristol Myers Squibb, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Others
Unit Denominations	USD Million/Billion

Besides, various initiatives by governments of different countries worldwide for increasing the awareness about the early cancer detection & treatment, coupled with rapid technological advancements associated with the healthcare sector, and the advent of more effective diagnostics & therapeutics for malignant melanoma treatment, are also projected to boost the market in the coming years.

In general, the risk of developing malignant melanoma rises with age. However, new cases have been increasing among the younger population, i.e., those below 40 years. Moreover, there's a constantly surging need for affordable therapeutics for melanoma treatment owing to its burgeoning cost.

Surgery is the preferred method to treat primary skin cancer, but it alone fails for patients with advanced metastatic melanoma and thus, requires enhanced therapeutics. In recent years, with an improved understanding of cancer biology, various new therapeutic agents with promising potential have emerged as effective treatments for advanced melanoma and, in turn, project remunerative prospects for the Global Malignant Melanoma Market through 2027.

Introduction
1. Research Process
2. Assumption
3. Market Segmentation
4. Market Definition
Executive Summary
Global Malignant Melanoma Market Trends & Insights
Global Malignant Melanoma Market Regulation & Policy, By Country
Global Malignant Melanoma Market Dynamics
1. Growth Drivers
2. Challenges
3. Impact Analysis
Global Malignant Melanoma Market Hotspot and Opportunities
Global Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
    1. Biopsy
    2. Blood Tests
    3. Lab Tests
    4. Imaging
  2. By Treatment
    1. Lymphadenectomy
    2. Metastasectomy
    3. Radiation Therapy
    4. Chemotherapy
    5. Immunotherapy
      1. Yervoy (Ipilimumab)
      2. Keytruda (Pembrolizumab)
      3. Opdivo (Nivolumab)
      4. Tecentriq (Atezolizumab)
      5. Relatlimab
    6. Targeted Therapy
      1. Mekinist (Trametinib)
      2. Tafinlar (Dabrafenib)
      3. Mektovi (Binimetinib)
      4. Braftovi (Encorafenib)
      5. Zelboraf (Vemurafenib)
      6. Others (Cotellic (Cobimetinib), etc.)
  3. By End-User
    1. Hospitals
    2. Clinics
    3. Specialty Cancer Centers
  4. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  5. By Company
    1. Competition Characteristics
    2. Revenue Shares
    3. Competitor Placement in MarkNtel Advisor’s Quadrant
North America Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Treatment
  3. By End-User
  4. By Country
    1. The US
    2. Canada
    3. Mexico
South America Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Treatment
  3. By End-User
  4. By Country
    1. Brazil
    2. Rest of Latin America
Europe Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Treatment
  3. By End-User
  4. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
Middle East & Africa Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Treatment
  3. By End-User
  4. By Country
    1. South Africa
    2. GCC
    3. Rest of Middle East & Africa
Asia-Pacific Malignant Melanoma Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Diagnosis
  2. By Treatment
  3. By End-User
  4. By Country
    1. China
    2. Japan
    3. India
    4. Australia
    5. South East Asia
    6. Rest of Asia-Pacific
Global Malignant Melanoma Market Key Strategic Imperatives for Success and Growth
Competitive Outlook
1. Competition Matrix
  1. By Application Portfolio
  2. Brand Specialization
  3. Target Markets
  4. Target by Applications
  5. Research & Development
  6. Strategic Alliances
  7. Strategic Initiatives
2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
  1. AstraZeneca PLC
  2. Amgen Inc.
  3. Bristol Myers Squibb
  4. F. Hoffmann-La Roche AG
  5. GlaxoSmithKline PLC
  6. Merck & Co., Inc.
  7. Novartis International AG
  8. Pfizer Inc.
  9. Sun Pharmaceutical Industries Ltd.
  10. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *